keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Clodronic acid disodium salt (Lodronate) 是一种口服具有活力的破骨细胞骨吸收 (osteoclastic bone resorption) 的抑制剂,是一代双磷酸盐。它可用于高骨转换状态、Paget’s 病和溶骨性骨转移中。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 148 | 现货 | ||
100 mg | ¥ 247 | 现货 | ||
200 mg | ¥ 397 | 现货 | ||
500 mg | ¥ 726 | 现货 |
产品描述 | Clodronic acid disodium salt (Lodronate), a bisphosphonate, is a potent antiosteolytic agent which inhibits bone resorption. |
体外活性 | Clodronate significantly decreases total viability of cultures of J774 cells with EC50 of 300 μM, while liposome-encapsulated Clodronate decreases total viability of cultures of J774 cells with EC50 of 1 μM. Clodronate and liposome-encapsulated Clodronate is metabolized to a nonhydrolyzable adenosine triphosphate (ATP) analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, which can be detected in J774 cell extracts by using fast protein liquid chromatography. [1] Clodronate induces apoptosis in isolated osteoclasts. Clodronate, when administered in liposomes, also induces apoptosis in rat peritoneal macrophages in vitro and in liver macrophages of mice in vivo but not in murine macrophage-like RAW-264 cells. [2] Clodronate delivered into macrophages by liposome will kill these cells as a result of intracellular accumulation and irreversible metabolic damage. [3] Clodronate encapsulated in liposomes (clodrolip) efficiently depletes the phagocytic cells in the murine F9 teratocarcinoma and human A673 rhabdomyosarcoma mouse tumour models resulting in significant inhibition of tumour growth ranging from 75 to >92%, depending on therapy and schedule. [4] Clodronate, a bisphosphonate that lacks a nitrogen, does not inhibit protein isoprenylation but can be metabolized intracellularly to a beta-gamma-methylene (AppCp-type) analog of ATP, which is cytotoxic to macrophages in vitro. Clodronate is metabolited to AppCCl(2)p, and AppCCl(2)p inhibits mitochondrial oxygen consumption by a mechanism that involves competitive inhibition of the ADP/ATP translocase. [5] |
别名 | Loron, Clodronate Disodium, 氯屈膦酸二钠, Lodronate |
分子量 | 288.86 |
分子式 | CH4Cl2O6P0·2Na |
CAS No. | 22560-50-5 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 58.82 mg/mL (203.64 mM), Sonication is recommended.
DMSO: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 3.4619 mL | 17.3094 mL | 34.6188 mL | 86.5471 mL |
5 mM | 0.6924 mL | 3.4619 mL | 6.9238 mL | 17.3094 mL | |
10 mM | 0.3462 mL | 1.7309 mL | 3.4619 mL | 8.6547 mL | |
20 mM | 0.1731 mL | 0.8655 mL | 1.7309 mL | 4.3274 mL | |
50 mM | 0.0692 mL | 0.3462 mL | 0.6924 mL | 1.7309 mL | |
100 mM | 0.0346 mL | 0.1731 mL | 0.3462 mL | 0.8655 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Clodronic acid disodium salt 22560-50-5 Others inhibit ADP Loron mitochondria Clodronate Disodium first-generation metastases cytochrome Paget’s 氯屈膦酸二钠 Inhibitor osteoclastic Lodronate resorption Clodronic acid disodium bone Clodronate Clodronic acid inhibitor